Taxell Therapeutics

Taxell Therapeutics is a South Korean biotechnology company specializing in the development of novel prodrug formulations of established chemotherapeutic agents. The company's core technology involves a peptide-linker system designed to improve the solubility, stability, and tumor-specific delivery of paclitaxel. Its lead candidate, TXL-001 (Pro-Taxol), aims to provide a more effective and less toxic alternative to conventional taxane therapies for patients with advanced solid tumors. By utilizing a cathepsin B-cleavable peptide, the drug is designed to release the active paclitaxel moiety specifically within the tumor microenvironment. Taxell's approach focuses on leveraging clinically validated mechanisms with improved delivery platforms to enhance patient outcomes in oncology.